Temasek Holdings Private Ltd Acquires 593,915 Shares of Boston Scientific Corporation $BSX

Temasek Holdings Private Ltd raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 54.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,679,326 shares of the medical equipment provider’s stock after purchasing an additional 593,915 shares during the period. Temasek Holdings Private Ltd owned 0.11% of Boston Scientific worth $163,953,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in Boston Scientific in the second quarter valued at $249,000. SBI Securities Co. Ltd. increased its position in Boston Scientific by 31.5% during the 2nd quarter. SBI Securities Co. Ltd. now owns 4,028 shares of the medical equipment provider’s stock valued at $433,000 after purchasing an additional 965 shares during the period. L & S Advisors Inc increased its position in Boston Scientific by 13.4% during the 2nd quarter. L & S Advisors Inc now owns 72,090 shares of the medical equipment provider’s stock valued at $7,743,000 after purchasing an additional 8,525 shares during the period. Finally, Advisors Capital Management LLC raised its holdings in Boston Scientific by 46.5% in the 2nd quarter. Advisors Capital Management LLC now owns 6,446 shares of the medical equipment provider’s stock worth $692,000 after purchasing an additional 2,046 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BSX shares. Wells Fargo & Company cut their target price on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. UBS Group decreased their price target on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday, February 5th. Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Royal Bank Of Canada reduced their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $108.00.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Stock Performance

Boston Scientific stock opened at $69.15 on Friday. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $102.61 billion, a P/E ratio of 35.64, a PEG ratio of 0.96 and a beta of 0.69. The stock’s 50 day moving average is $82.47 and its 200 day moving average is $93.39.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the previous year, the company posted $0.70 earnings per share. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.